1. Scrip
  2. >>Business

Amgen Hands Omecamtiv Back To Cytokinetics

Cytokinetics Assessing Commercializing On Its Own Or With New Partner

 
• By Mandy Jackson

While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.

Two female hands holding a 3d printed human heart
Amgen handed omecamtiv mecarbil back to Cytokinetics after data didn't meet a "high bar" in a Phase III heart failure trial • Source: Shutterstock

After reviewing initial data from the Phase III GALACTIC-HF clinical trial of omecamtiv mecarbil in heart failure with reduced ejection fraction (HFrEF), Amgen, Inc. determined that the results were not compelling enough to move forward with regulatory filings and commercialization of the cardiac myosin activator. It revealed 23 November that it will give its rights to the drug back to Cytokinetics, Inc.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Novartis Gains Further Renal Territory With Regulus Acquisition

 
• By Alaric DeArment

The San Diego biotech’s lead product candidate is an antisense oligonucleotide-based therapy slated to enter Phase III development in the third quarter.

In Brief: Merck To Invest $1bn In New US Biologics Production

 
• By Sushmita Panda

Merck is investing $ 1bn in a Delaware facility to produce Keytruda and expand biologics manufacturing amid US tariff concerns.

Can European Biotech Survive And Thrive In Era Of Instability?

 
• By Andrew McConaghie

Europe's biopharma sector could suffer if the Trump administration incentivizes US investment but VC leaders believe the region can still thrive and potentially capitalize on instability elsewhere.